Phase Ib/II trial evaluating durvalumab in combination with AZD9150 or AZD5069 in anti-PD-1/PD-L1 naïve patients with advanced/metastatic HNSCC. In 38 patients in the AZD9150 cohort, ORR was 26%, including 4 complete responders. In 20 patients of AZD5069 cohort, ORR was 10%. (NCT02499328). This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.